Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 118, Issue 7, 2011, Pages 814-824

  Manchanda, R ^a   Abdelraheim, A ^b,c   Johnson, M ^a   Rosenthal, A N ^a   Benjamin, E ^d   Brunell, C ^e   Burnell, M ^a   Side, L ^a   Gessler, S ^a   Saridogan, E ^e   Oram, D ^b   Jacobs, I ^a   Menon, U ^a,f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c MINIA UNIVERSITY HOSPITAL   (Egypt)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f EGA Institute for Womens Health   (United Kingdom)

Author keywords

BRCA; occult cancer; ovarian cancer; risk reducing salpingo oophorectomy; tubal cancer; unknown mutation status

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CANCER SCREENING; CARCINOMA IN SITU; FEMALE; GENE MUTATION; HETEROZYGOTE DETECTION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

ADULT; AGED; CARCINOMA IN SITU; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HETEROZYGOTE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; LAPAROSCOPY; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; OVARIECTOMY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SALPINGECTOMY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955975428     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2011.02920.x     Document Type: Article

References (40)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30. (Pubitemid 36530000)
2. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33. (Pubitemid 46706879)
3. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al., Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006; 24: 863-71. (Pubitemid 46638837)
4. King MC, Marks JH, Mandell JB,. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-6. (Pubitemid 37310920)
5. Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, et al., Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004; 12: 899-906. (Pubitemid 39462123)
6. Rennert G, Dishon S, Rennert HS, Fares F,. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel. Eur J Cancer Prev 2005; 14: 357-61. (Pubitemid 41104944)
7. Rebbeck TR, Kauff ND, Domchek SM,. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-7.
8. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al., Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296: 185-92.
9. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al., Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-90. (Pubitemid 47477278)
10. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ,. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100: 58-64. (Pubitemid 41815050)
11. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM,. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 2006; 194: 1702-9. (Pubitemid 43766909)
12. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, et al., Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23: 127-32. (Pubitemid 41702631)
13. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-22. (Pubitemid 34755669)
14. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, et al., Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 2006; 108: 515-20. (Pubitemid 44337090)
15. Crum CP,. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol 2009; 3: 165-70.
16. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al., Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-9. (Pubitemid 46175016)
17. Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, et al., Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90: 1492-7. (Pubitemid 38648227)
18. Agoff SN, Mendelin JE, Grieco VS, Garcia RL,. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002; 26: 171-8. (Pubitemid 34127496)
19. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B,. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001; 25: 1283-9. (Pubitemid 32917122)
20. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P,. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87: 52-6. (Pubitemid 36027101)
21. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, et al., Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 18: 2728-32. (Pubitemid 30463555)
22. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, et al., Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996; 88: 1810-20. (Pubitemid 26425055)
23. Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW,. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005; 97: 476-82. (Pubitemid 40614892)
24. Stratton JF, Buckley CH, Lowe D, Ponder BA,. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst 1999; 91: 626-8. (Pubitemid 29194049)
25. Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, et al., ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006; 24: 4642-60. (Pubitemid 46630963)
26. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al., The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9. (Pubitemid 46095865)
27. Dubeau L,. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008; 9: 1191-7.
28. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, et al., Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008; 27: 1-9. (Pubitemid 351627965)
29. Antill Y, Reynolds J, Young MA, Kirk J, Tucker K, Bogtstra T, et al., Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. Eur J Cancer 2006; 42: 621-8. (Pubitemid 43343684)
30. Phillips KA, Jenkins MA, Lindeman GJ, McLachlan SA, McKinley JM, Weideman PC, et al., Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 2006; 70: 198-206. (Pubitemid 44219507)
31. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15. (Pubitemid 34755668)
32. Bishoff JT, Allaf ME, Kirkels W, Moore RG, Kavoussi LR, Schroder F,. Laparoscopic bowel injury: incidence and clinical presentation. J Urol 1999; 161: 887-90. (Pubitemid 29422388)
33. Kauff ND, Barakat RR,. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 2007; 25: 2921-7. (Pubitemid 47123156)
34. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, et al., International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008; 122: 2017-22. (Pubitemid 351441190)
35. Wainberg S, Husted J,. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 2004; 13: 1989-95. (Pubitemid 40054290)
36. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, et al., Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 2009; 18: 2318-24.
37. CRUK. CancerStats, ovarian cancer UK. 2004 []. Last Accessed 5 March 2010.
38. ACOG. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009; 113: 957-66.
39. Nelson HD, Huffman LH, Fu R, Harris EL,. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 143: 362-79.
40. NICE. Familial Breast Cancer: The Classification and Care of Women at Risk of Familial Breast Cancer in Primary, Secondary and Tertiary Care. London: National Institute for Health and Clinical Excellence, 2006.